Adapted from Hearing: Examining Policies that Inhibit Innovation and Patient Access, Before the House Subcommittee on Health of the Committee on Ways and Means, 118^th Cong. (2023) (statement of Aaron Kesselheim, Harvard Medical School professor).Google Scholar

Cleary, E. Galkina et al., “Contribution of NIH Funding to New Drug Approvals 2010–2016,” Proceedings of the National Academy of Sciences 115, no. 10 (2018): 2329–2334.Google Scholar

Cleary, E. Galkina et al., “Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010–2019,” JAMA Health Forum 4, no. 4 (2023): e230511.Google Scholar

Barenie, R.E. et al., “Public Funding for Transformative Drugs: the Case of Sofosbuvir,” Drug Discovery Today 26, no. 1 (2021): 273–281.Google ScholarPubMed

Nayak, R.K., Avorn, J., and Kesselheim, A.S., “Public Sector Financial Support for Late Stage Discovery of New Drugs in the United States: cohort study,” BMJ 367 (2019): 157–166.Google ScholarPubMed

Nayak, R.K. et al., “Public-Sector Contributions to Novel Biologic Drugs,” JAMA Internal Medicine 181, no. 11 (2021): 1522–1525.CrossRefGoogle ScholarPubMed

Tessema, F.A. et al., “Federal Funding for Discovery and Development of Costly HIV Drugs Was Far More Than Previously Estimated,” Health Affairs 42, no. 5 (2023): 642–649.CrossRefGoogle ScholarPubMed

Barenie, R.E. and Kesselheim, A.S., “Buprenorphine for Opioid Use Disorder: the Role of Public Funding in Its Development,” Drug and Alcohol Dependence 219 (2021): 108491.CrossRefGoogle ScholarPubMed

Sampat, B.N., “Academic Patents and Access to Medicines in Developing Countries,” American Journal of Public Health 99 (2009): 9–17.CrossRefGoogle ScholarPubMed

Kesselheim, A.S. and Avorn, J., “The Most Transformative Drugs of the Past 25 Years: a Survey of Physicians,” Nature Reviews: Drug Discovery 12, no. 6 (2013): 425–431.Google Scholar

Kesselheim, A.S., Tan, Y.T., and Avorn, J., “The Roles of Academia, Rare Diseases, and Repurposing in the Development of the Most Transformative Drugs,” Health Affairs 34 no 2 (2015): 286–94.Google ScholarPubMed

Lalani, H.S. et al., “US Public Investment in Development of mRNA COVID-19 Vaccines: Retrospective Cohort Study,” BMJ 380 (2023): e073747.CrossRefGoogle ScholarPubMed

Love, J., Novartis, Dana Farber, Oregon Health & Science University Wait 18 Years to Disclose NIH Funding in Key Gleevec Patent (October 11, 2019), Bill of Health, the blog of the Petrie-Flom Center at Harvard Law School, available at <https://blog.petrieflom.law.harvard.edu/2019/10/11/novartis-dana-farber-oregon-health-science-university-wait-18-years-to-disclose-nih-funding-in-key-gleevec-patent/> (last visited September 6, 2023).+(last+visited+September+6,+2023).>Google Scholar

Druker, B.J., “Perspectives on the Development of Imatinib and the Future of Cancer Research,” Nature Medicine 15, no. 10 (2009): 1149–1152.CrossRefGoogle ScholarPubMed

Russell, S. et al., “Efficacy and Safety of Voretigene Neparvovec (AAV2-hRPE65v2) in Patients with RPE65-Mediated Inherited Retinal Dystrophy: a Randomised, Controlled, Open-Label, Phase Three Trial,” Lancet 390, no. 10097 (2017): 849–860.CrossRefGoogle Scholar

Schuster, S.J. et al., “Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma,” New England Journal of Medicine 380, no. 1 (2019): 45–56.Google ScholarPubMed

Vokinger, K.N., Avorn, J., and Kesselheim, A.S., “Sources of Innovation in Gene Therapies — Approaches to Achieving Affordable Prices,” New England Journal of Medicine 388, no. 4 (2023): 292–295.CrossRefGoogle ScholarPubMed

Newham, M. and Vokinger, K.N., “Adverse Effects of Acquisitions in the Pharmaceutical Industry,” Nature Medicine 28, no. 7 (2022): 1342–1344.CrossRefGoogle ScholarPubMed

Mullard, A., 2022 FDA Approvals (January 3, 2023), Nature Reviews Drug Discovery, available at <https://doi.org/10.1038/d41573-023-00001-3> (last visited September 6, 2023).CrossRef+(last+visited+September+6,+2023).>Google Scholar

Hwang, T.J. et al., “Association Between FDA and EMA Expedited Approval Programs and Therapeutic Value of New Medicines: Retrospective Cohort Study,” BMJ 371 (2020): m3434.CrossRefGoogle ScholarPubMed

Rome, B.N., Egilman, A., and Kesselheim, A.S., “Trends in Prescription Drug Launch Prices, 2008–2021,” JAMA 327, no. 21 (2022): 2145–2147.CrossRefGoogle ScholarPubMed

Some of these new drugs are effective but are just second- or later-in-class products. Such products may offer some utility to patients, such as those who cannot tolerate the first-in-class product, and can have pro-competitive benefits even without being direct competitors, so we could offer more tailored incentives for their production.Google Scholar

Patel, N. et al., “Therapeutic Value of Drugs Frequently Marketed Using Direct-to-Consumer Television Advertising, 2015–2021,” JAMA Network Open 6, no. 1 (2023): e2250991.CrossRefGoogle Scholar

Egilman, A.C., Rome, B.N., and Kesselheim, A.S., “Added Therapeutic Benefit of Top-Selling Brand-Name Drugs in Medicare,” JAMA 329, no. 15 (2023): 1283–1289.CrossRefGoogle ScholarPubMed

Kesselheim, A.S., Avorn, J., and Sarpatwari, A., “The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” JAMA 316, no. 8 (2016): 858–871.CrossRefGoogle ScholarPubMed

Alzheimer’s Disease Fact Sheet (April 5, 2023), NIH National Institute on Aging, available at <https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet> (last visited September 6, 2023).+(last+visited+September+6,+2023).>Google Scholar

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (ENGAGE), ClinicalTrials.gov, available at <https://classic.clinicaltrials.gov/ct2/show/NCT02477800> (last visited September 6, 2023); 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (EMERGE), ClinicalTrials.gov, available at <https://classic.clinicaltrials.gov/ct2/show/NCT02484547> (last visited September 6, 2023).+(last+visited+September+6,+2023);+221AD302+Phase+3+Study+of+Aducanumab+(BIIB037)+in+Early+Alzheimer’s+Disease+(EMERGE),+ClinicalTrials.gov,+available+at++(last+visited+September+6,+2023).>Google Scholar

Woloshin, S. and Kesselheim, A.S., “What to Know About the Alzheimer Drug Aducanumab (Aduhelm),” JAMA Internal Medicine 182, no. 8 (2022): 892.CrossRefGoogle ScholarPubMed

In the low-dose aducanumab arm in Study 302, the effect was not statistically significant, again precluding the ability to assess efficacy with respect to secondary outcomes among both the high- and low-dose treatment arms. Alexander, G. C. et al., “Revisiting FDA Approval of Aducanumab,” New England Journal of Medicine 385, no. 9 (2021): 769–771.Google ScholarPubMed

Andrews, J.S. et al., “Disease Severity and Minimal Clinically Important Differences in Clinical Outcome Assessments for Alzheimer’s disease Clinical Trials,” Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019): 354–363.Google ScholarPubMed

Belluck, P., Kaplan, S., and Robbins, R., “How an Unproven Alzheimer’s Drug Got Approved,” New York Times, July 19, 2021, available at <https://www.nytimes.com/2021/07/19/health/alzheimers-drug-aduhelm-fda.html> (last visited September 6, 2023).Google Scholar

Chiong, W. et al., “Decisions with Patients and Families Regarding Aducanumab in Alzheimer Disease, with Recommendations for Consent: AAN Position Statement,” Neurology 98 no. 4 (2022): 154–159.CrossRefGoogle ScholarPubMed

Cavazzoni, P., FDA’s Decision to Approve New Treatment for Alzheimer’s Disease (June 7, 2021), U.S. Food and Drug Administration, available at <https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease> (last visited September 6, 2023).+(last+visited+September+6,+2023).>Google Scholar

U.S. House of Representatives Committee on Oversight and Reform and Committee on Energy and Commerce, The High Price of Aduhelm’s Approval: an Investigation into FDA’s Atypical Review Process and Biogen’s Aggressive Launch Plans, December 2022, available at <https://oversightdemocrats.house.gov/sites/democrats.oversight.house.gov/files/2022-12-29.COR%20%26%20E%26C%20Joint%20Staff%20Report%20re.%20Aduhelm.pdf> (last visited September 6, 2023), at 5.+(last+visited+September+6,+2023),+at+5.>Google Scholar

Cubanski, J. and Newman, T., Relatively Few Drugs Account for a Large Share of Medicare Prescription Drug Spending (April 19, 2021), Kaiser Family Foundation, available at <https://www.kff.org/medicare/issue-brief/relatively-few-drugs-account-for-a-large-share-of-medicare-prescription-drug-spending/> (last visited September 6, 2023).+(last+visited+September+6,+2023).>Google Scholar

See Chiong, supra note 32.Google Scholar

Katz, J., Kliff, S., and Sanger-Katz, M., “Drug could cost the government as much as it spends on NASA,” New York Times, June 22, 2021, available at <https://www.nytimes.com/2021/06/22/upshot/alzheimers-aduhelm-medicare-cost.html> (last visited September 6, 2023).+(last+visited+September+6,+2023).>Google Scholar

U.S. Centers for Medicare and Medicaid Services, Innovation Models, available at <https://innovation.cms.gov/innovation-models#views=models> (last visited September 6, 2023).+(last+visited+September+6,+2023).>Google Scholar

Darrow, J.J., Avorn, J., and Kesselheim, A.S., “New FDA Breakthrough-Drug Category — Implications for Patients,” New England Journal of Medicine 370, no. 13 (2014): 1252–1258.CrossRefGoogle ScholarPubMed

Deshmukh, A.D., Kesselheim, A.S., and Rome, B.N., “Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021,” JAMA Health Forum 4, no. 3 (2023): e230217.Google ScholarPubMed

Gyawali, B., Hey, S.P., and Kesselheim, A.S., “Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval,” JAMA Internal Medicine 179, no. 7 (2019): 906–913.Google ScholarPubMed

Perrone, M., “The FDA’s Speedy Approval of Experimental New Drugs Came to a Screeching Halt This Year,” Fortune, December 7, 2022, available at <https://fortune.com/2022/12/07/fda-accelerated-pathway-speedy-approval-experimental-drugs-slows-2022-this-year/> (last visited September 6, 2023).+(last+visited+September+6,+2023).>Google Scholar

Gellad, W. F. and Kesselheim, A. S., “Accelerated Approval and Expensive Drugs — a Challenging Combination,” New England Journal of Medicine 376, no. 21 (2017): 2001–2004.CrossRefGoogle ScholarPubMed

Cohen, J., “Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small,” Forbes, December 2, 2022, available at <https://www.forbes.com/sites/joshuacohen/2022/12/02/despite-eye-popping-35-million-price-tag-for-gene-therapy-hemgenix-budget-impact-for-most-payers-will-be-relatively-small/> (last visited September 6, 2023).+(last+visited+September+6,+2023).>Google Scholar

Verma, M. and Somia, N., “Gene Therapy – Promises, Problems and Prospects,” Nature 389, no. 6648 (1997): 239–242.CrossRefGoogle Scholar

Mahlangu, J. et al., “Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A,” New England Journal of Medicine 388, no. 8 (2023): 694–705.Google ScholarPubMed

Sterner, R.C. and Sterner, R. M., “CAR-T Cell Therapy: Current Limitations and Potential Strategies,” Blood Cancer Journal 11, no. 4 (2021): 69.CrossRefGoogle ScholarPubMed

Choudhry, N.K. et al., “Full Coverage for Preventive Medications after Myocardial Infarction,” New England Journal of Medicine 365, no. 22 (2011): 2088–2097; J. J. Gagne et al., “Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes: a Cohort Study,” Annals of Internal Medicine 161, no. 6 (2014): 400–408.Google ScholarPubMed

Patel, A.N., Kesselheim, A.S., and Rome, B.N., “Frequency of Generic Drug Price Spikes and Impact on Medicaid Spending,” Health Affairs 40, no. 5 (2021): 779–785.CrossRefGoogle ScholarPubMed

Kesselheim, A.S. and Hwang, T.J., “Breakthrough Medical Devices and the 21st Century Cures Act,” Annals of Internal Medicine 164, no. 7 (2016): 500–502.Google ScholarPubMed

U.S. Food and Drug Administration, Breakthrough Devices Program: Guidance of Industry and Food and Drug Administration Staff, December 18, 2018, available at <https://www.fda.gov/media/162413/download> (last visited October 31, 2023), at 12.+(last+visited+October+31,+2023),+at+12.>Google Scholar

Johnston, J.L., Dhruva, S.S., Ross, J.S., and Rathi, V.K., “Early Experience with the FDA’s Breakthrough Devices Program,” Nature Biotechnology 38 ( 2020): 933–938.Google ScholarPubMed

Rathi, V.K., Johnston, J.L., Ross, J.S., and Dhruva, S.S., “Medicare’s New Device-Coverage Pathway — Breakthrough or Breakdown?,” New England Journal of Medicine 384, no. 12 (2021): e43.CrossRefGoogle ScholarPubMed

Firth, S., “Democratic Senators Rebuke Cuts to NIH in House-Passed Bill,” MedPage Today, May 5, 2023, available at <https://www.medpagetoday.com/washington-watch/washington-watch/104356> (last visited September 6, 2023).+(last+visited+September+6,+2023).>Google Scholar